Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07611110 · ClinicalTrials.gov registry record · Phase 3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
A Phase 3 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 670
- Enrollment target
NCT07611110 is a Phase 3 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 670 participants.
The verdict
NCT07611110, a Phase 3 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 670 participants
- Enrollment target
Study Summary
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Interventions
- DRUG Apalutamide
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG Cabazitaxel
- DRUG AZD2265
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2026-05-04 |
| Est. Completion | 2029-12-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07611110
The ClinicalTrials.gov registry entry for NCT07611110 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Apalutamide is the first listed.
NCT07611110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07611110 about?
NCT07611110 is a clinical study titled "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)". The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
What is the current status of trial NCT07611110?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 670 participants. The study started on 2026-05-04. Estimated completion is 2029-12-20.
What interventions are being tested in trial NCT07611110?
The interventions under investigation include: Apalutamide (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), Cabazitaxel (DRUG), AZD2265 (DRUG).
Who is sponsoring clinical trial NCT07611110?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.